跳至主要内容
临床试验/ITMCTR2200005552
ITMCTR2200005552招募中未知

A prospective, controlled, Real-World cohort study to evaluate the overall survival and progression-free survival of HBV-related primary liver cancer in the middle and late stages of the standard treatment of the optimized regimen of integrated traditional Chinese and western medicine

The Affiliated Traditional Chinese Medicine Hospital Of Southwest Medical University0 个研究点开始时间: 待定最近更新:
适应症

试验速览

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 75(—)
性别
All

入选标准

  • ?Meet the diagnostic criteria of chronic hepatitis B; ?Meet the diagnostic criteria of primary liver cancer; ?Barcelona stage B-D, can accept standardized treatment procedures; ?age =18 years old, =75 years old; ?sign informed consent.

排除标准

  • ?Patients with severe acute and chronic diseases, including myocardial infarction, stroke, heart failure, uncontrolled diabetes and HIV, etc.; ?Co-infection with other viral hepatitis, severe alcoholic liver disease, autoimmune liver disease, severe fatty liver disease, etc. Patients with other liver diseases; ?A history of drug abuse or mental illness; ?Received other research or anti-tumor drugs in the past 4 weeks; ?Pregnant or lactating women.

研究者

相似试验